Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Income from Continuing Operations: 2013-2024

Historic Income from Continuing Operations for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to -$413.6 million.

  • ImmunityBio's Income from Continuing Operations rose 21.55% to -$67.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$348.7 million, marking a year-over-year increase of 40.68%. This contributed to the annual value of -$413.6 million for FY2024, which is 29.15% up from last year.
  • ImmunityBio's Income from Continuing Operations amounted to -$413.6 million in FY2024, which was up 29.15% from -$583.9 million recorded in FY2023.
  • In the past 5 years, ImmunityBio's Income from Continuing Operations ranged from a high of -$224.2 million in FY2020 and a low of -$583.9 million during FY2023.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$417.3 million (2022), whereas its average is -$471.6 million.
  • As far as peak fluctuations go, ImmunityBio's Income from Continuing Operations slumped by 56.05% in 2021, and later grew by 29.15% in 2024.
  • ImmunityBio's Income from Continuing Operations (Yearly) stood at -$224.2 million in 2020, then plummeted by 56.05% to -$349.8 million in 2021, then declined by 19.29% to -$417.3 million in 2022, then tumbled by 39.91% to -$583.9 million in 2023, then rose by 29.15% to -$413.6 million in 2024.